Literature DB >> 27489878

Untangling tau imaging.

Victor L Villemagne1, Nobuyuki Okamura2, Christopher C Rowe3.   

Abstract

In vivo imaging of tau deposits is providing a better understanding of the temporal and spatial tau deposition in the brain, allowing a more comprehensive insight into the causes, diagnoses, and potentially treatment of tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. The assessment of tau deposition in the brain over time will allow a deeper understanding of the relationship between tau and other variables such as cognition, genotype, and neurodegeneration, as well as assessing the role tau plays in ageing. Preliminary human studies suggest that tau imaging could also be used as a diagnostic, prognostic, and theranostic biomarker, as well as a surrogate marker for target engagement, patient recruitment, and efficacy monitoring for disease-specific therapeutic trials.

Entities:  

Keywords:  Alzheimer's disease; Dementia; PET; Positron emission tomography; Tau imaging; Tauopathies

Year:  2016        PMID: 27489878      PMCID: PMC4961897          DOI: 10.1016/j.dadm.2016.05.001

Source DB:  PubMed          Journal:  Alzheimers Dement (Amst)        ISSN: 2352-8729


  81 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

Review 2.  Update on Hippocampal Sclerosis.

Authors:  Juliana R Dutra; Etty P Cortés; Jean Paul G Vonsattel
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

3.  Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

Authors:  Nobuyuki Okamura; Shozo Furumoto; Michelle T Fodero-Tavoletti; Rachel S Mulligan; Ryuichi Harada; Paul Yates; Svetlana Pejoska; Yukitsuka Kudo; Colin L Masters; Kazuhiko Yanai; Christopher C Rowe; Victor L Villemagne
Journal:  Brain       Date:  2014-03-27       Impact factor: 13.501

4.  Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease.

Authors:  Nobuyuki Okamura; Takahiro Suemoto; Shozo Furumoto; Masako Suzuki; Hiroshi Shimadzu; Hiroyasu Akatsu; Takayuki Yamamoto; Hironori Fujiwara; Miyako Nemoto; Masahiro Maruyama; Hiroyuki Arai; Kazuhiko Yanai; Tohru Sawada; Yukitsuka Kudo
Journal:  J Neurosci       Date:  2005-11-23       Impact factor: 6.167

5.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model.

Authors:  Bin Zhang; Arpita Maiti; Sharon Shively; Fara Lakhani; Gaye McDonald-Jones; Jennifer Bruce; Edward B Lee; Sharon X Xie; Sonali Joyce; Chi Li; Philip M Toleikis; Virginia M-Y Lee; John Q Trojanowski
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-22       Impact factor: 11.205

Review 6.  Tau protein pathology in neurodegenerative diseases.

Authors:  M G Spillantini; M Goedert
Journal:  Trends Neurosci       Date:  1998-10       Impact factor: 13.837

7.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

8.  Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin.

Authors:  Hans Zempel; Julia Luedtke; Yatender Kumar; Jacek Biernat; Hana Dawson; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  EMBO J       Date:  2013-09-24       Impact factor: 11.598

9.  Postmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging.

Authors:  Lojze M Smid; Vladimir Kepe; Harry V Vinters; Mara Bresjanac; Tatsushi Toyokuni; Nagichettiar Satyamurthy; Koon-Pong Wong; Sung-Cheng Huang; Daniel H S Silverman; Karen Miller; Gary W Small; Jorge R Barrio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.

Authors:  Michelle T Fodero-Tavoletti; Shozo Furumoto; Leanne Taylor; Catriona A McLean; Rachel S Mulligan; Ian Birchall; Ryuichi Harada; Colin L Masters; Kazuhiko Yanai; Yukitsuka Kudo; Christopher C Rowe; Nobuyuki Okamura; Victor L Villemagne
Journal:  Alzheimers Res Ther       Date:  2014-02-26       Impact factor: 6.982

View more
  1 in total

1.  Temporal dynamics of animacy categorization in the brain of patients with mild cognitive impairment.

Authors:  Hamed Karimi; Haniyeh Marefat; Mahdiyeh Khanbagi; Chris Kalafatis; Mohammad Hadi Modarres; Zahra Vahabi; Seyed-Mahdi Khaligh-Razavi
Journal:  PLoS One       Date:  2022-02-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.